AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22459966 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran 4 mg
Number of subjects: 64
Study 22459966 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran 12 mg
Number of subjects: 64
Study 22459966 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran 28 mg
Number of subjects: 64
Study 22459966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22459966 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran (all doses)
Number of subjects: 64
Study 20855800 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (180 µg per kg of body weight) administered intravenously as a single dose 3 days before each chemotherapy cycle (maximum, 6 cycles)
Number of subjects: 48
Study 18249119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (various agents and schedules)
Number of subjects: 828
Study 18249119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy clinical trial
Number of subjects: 828
Study 18249119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in patients over 60 years
Number of subjects: 828
Study 15979448 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 47
Study 15979448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12915290 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5-15 mg daily
Number of subjects: 60
Study 12915290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10952748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection
Number of subjects: 21
Study 10952748 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive flexion
Number of subjects: 21
Study 10952748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritchie pain score
Number of subjects: 21
Study 10952748 — intervention group
Group type: EXPERIMENTAL
Intervention: Swelling
Number of subjects: 21
Study 10952748 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Impact Measurements Scales question about buttoning clothes
Number of subjects: 21
Study 10952748 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale questions about activity of the disease
Number of subjects: 21
Study 10952748 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale questions about swelling of the joint
Number of subjects: 21
Study 8970781 — intervention group
Group type: EXPERIMENTAL
Intervention: Semipermeable glove
Number of subjects: 46
Study 8970781 — intervention group
Group type: COMPARATOR
Intervention: Standard cotton glove
Number of subjects: 46
Study 1580295 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin E
Number of subjects: 18
Study 1580295 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 18
Study 6374682 — intervention group
Group type: EXPERIMENTAL
Intervention: miconazole/hydrocortisone preparation
Number of subjects: 62
Study 6374682 — intervention group
Group type: COMPARATOR
Intervention: nystatin/benzalkonium chloride/dimethicone/hydrocortisone preparation
Number of subjects: 62
Study 2876035 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef 6g daily for 7 days
Number of subjects: 0
Study 2876035 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef 3g daily for 7 days
Number of subjects: 0
Study 30569673 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperPATH approach
Number of subjects: 24
Study 30569673 — intervention group
Group type: COMPARATOR
Intervention: posterolateral approach
Number of subjects: 24
Study 26538525 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide group (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg)
Number of subjects: 1443
Study 26538525 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate group (previous regimens)
Number of subjects: 1443
Study 26538525 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide group
Number of subjects: 1443
Study 26538525 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate group
Number of subjects: 1443
Study 25547513 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line educational intervention to improve financial abuse detection (n = 78)
Number of subjects: 154
Study 25547513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no on-line educational intervention, n = 76)
Number of subjects: 154
Study 25547513 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line educational intervention
Number of subjects: 154
Study 22697193 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (LAI)
Number of subjects: 369
Study 20420113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (1 gram of dried powder suspended in 100 ml water)
Number of subjects: 14
Study 20420113 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 14
Study 18689435 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous olfactory ensheathing cell transplantation
Number of subjects: 6
Study 18689435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 6
Study 18689435 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant recipient
Number of subjects: 6
Study 15659136 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid avoidance (SA) with basiliximab, cyclosporine (CsA), and mycophenolate mofetil (MMF)
Number of subjects: 77
Study 15659136 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid avoidance (SA)
Number of subjects: 77
Study 15659136 — intervention group
Group type: COMPARATOR
Intervention: Control group with steroids tapered to 5 mg prednisone/d by day 30
Number of subjects: 77
Study 12929057 — intervention group
Group type: EXPERIMENTAL
Intervention: TSC-EGD
Number of subjects: 150
Study 12929057 — intervention group
Group type: EXPERIMENTAL
Intervention: PSC-EGD
Number of subjects: 150
Study 12929057 — intervention group
Group type: COMPARATOR
Intervention: C-EGD
Number of subjects: 150
Study 11125660 — intervention group
Group type: EXPERIMENTAL
Intervention: Leader briefings
Number of subjects: 237
Study 11125660 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-interaction training
Number of subjects: 237
Study 11125660 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel environments
Number of subjects: 237
Study 11125660 — intervention group
Group type: COMPARATOR
Intervention: Routine environments
Number of subjects: 237
Study 8931612 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program delivered by female Cherokee lay health educators
Number of subjects: 996
Study 8931612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education program)
Number of subjects: 996
Study 8931612 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 996
Study 1327609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR 50/200
Number of subjects: 84
Study 1327609 — intervention group
Group type: COMPARATOR
Intervention: Sinemet STD 25/100
Number of subjects: 84
Study 2997387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal high-dose interferon
Number of subjects: 68
Study 2997387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal low-dose interferon
Number of subjects: 68
Study 2997387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30892615 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Advancement (MA)
Number of subjects: 48
Study 30892615 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Advancement (IA)
Number of subjects: 48
Study 30222122 — intervention group
Group type: EXPERIMENTAL
Intervention: Left distal transradial approach (ldTRA)
Number of subjects: 200
Study 27070229 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 55
Study 27070229 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized LASIK
Number of subjects: 55
Study 25236994 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (sunitinib)
Number of subjects: 0
Study 25236994 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 22358993 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, 5-fluorouracil)
Number of subjects: 51
Study 22358993 — intervention group
Group type: COMPARATOR
Intervention: TACE with epirubicin
Number of subjects: 51
Study 20163368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg (Group B)
Number of subjects: 88
Study 20163368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (Group B)
Number of subjects: 88
Study 20163368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Group A)
Number of subjects: 88
Study 17403436 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (n = 9)
Number of subjects: 16
Study 17403436 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent and combined treatments
Number of subjects: 16
Study 17403436 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy
Number of subjects: 16
Study 17403436 — intervention group
Group type: COMPARATOR
Intervention: Metformin (n = 6)
Number of subjects: 16
Study 16234141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 mug every 6 h for a maximum of two doses)
Number of subjects: 120
Study 16234141 — intervention group
Group type: COMPARATOR
Intervention: Intracervical Foley balloon catheter (for 12 h followed by intravenous oxytocin infusion)
Number of subjects: 120
Study 16234141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 120
Study 16234141 — intervention group
Group type: COMPARATOR
Intervention: Intracervical Foley balloon catheter
Number of subjects: 120
Study 16234141 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 120
Study 12163990 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective lymph node dissection after hyperfractionated accelerated radio-(chemo-)therapy
Number of subjects: 87
Study 12163990 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective lymph node dissection
Number of subjects: 87
Study 12163990 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated accelerated radio-(chemo-)therapy
Number of subjects: 87
Study 10793877 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium pamidronate 300 mg/day for 4 weeks every 16 weeks (group A)
Number of subjects: 122
Study 10793877 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium pamidronate 150 mg/day for 4 weeks every 8 weeks (group B)
Number of subjects: 122
Study 10793877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 122
Study 8992677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine orally for five days every four weeks, median of four series
Number of subjects: 10
Study 8992677 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation period of 22 months with cladribine treatment
Number of subjects: 10
Study 1450064 — intervention group
Group type: EXPERIMENTAL
Intervention: PAVe (procarbazine, Alkeran, vinblastine) and irradiation (RT)
Number of subjects: 159
Study 1450064 — intervention group
Group type: EXPERIMENTAL
Intervention: PAVe/RT
Number of subjects: 159
Study 3841315 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intrathecal morphine
Number of subjects: 60
Study 3841315 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intrathecal morphine
Number of subjects: 60
Study 3841315 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 29687898 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency pulsed current (PC) NMES
Number of subjects: 11
Study 29687898 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-frequency current (MF) NMES
Number of subjects: 11
Study 29687898 — intervention group
Group type: COMPARATOR
Intervention: Both PC and MF NMES
Number of subjects: 11
Study 28343401 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium animalis subspecies lactis Bl‐04)
Number of subjects: 152
Study 28343401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 26143234 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm mini-tablet
Number of subjects: 151
Study 26143234 — intervention group
Group type: EXPERIMENTAL
Intervention: syrup
Number of subjects: 151
Study 26143234 — intervention group
Group type: EXPERIMENTAL
Intervention: suspension
Number of subjects: 151
Study 26143234 — intervention group
Group type: EXPERIMENTAL
Intervention: powder
Number of subjects: 151
Study 26143234 — intervention group
Group type: EXPERIMENTAL
Intervention: joint administration with food or drink
Number of subjects: 151
Study 23520237 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer Package (TP)
Number of subjects: 40
Study 23520237 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer Package (TP) and training by shaping
Number of subjects: 40
Study 23520237 — intervention group
Group type: COMPARATOR
Intervention: Weekly telephone contact (substudy)
Number of subjects: 40
Study 21878843 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally for up to 12 weeks
Number of subjects: 16
Study 18543496 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage with manipulation of supplementing marrow and kneading tendon (SMKT)
Number of subjects: 60
Study 18543496 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training therapy alone (Control)
Number of subjects: 60
Study 17073204 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose (SMP)
Number of subjects: 0
Study 17073204 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSE)
Number of subjects: 0
Study 17073204 — intervention group
Group type: COMPARATOR
Intervention: Comparison between SMP and CSE
Number of subjects: 0
Study 12969104 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion containing ropivacaine (1 mg.ml‐1), fentanyl (2 micro g.ml‐1), and epinephrine (2 micro g.ml‐1) for group RFE.
Number of subjects: 46
Study 12969104 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion without epinephrine for group RF.
Number of subjects: 46
Study 10717247 — intervention group
Group type: EXPERIMENTAL
Intervention: 120FEC (120 mg/m2 of epirubicin)
Number of subjects: 74
Study 10717247 — intervention group
Group type: COMPARATOR
Intervention: 60FEC (60 mg/m2 of epirubicin)
Number of subjects: 74
Study 9443096 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA monotherapy
Number of subjects: 41
Study 9443096 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA polytherapy
Number of subjects: 41
Study 9443096 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 41
Study 8112200 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP plasters (diclofenac hydroxyethylpyrrolidine), 180 mg each, applied b.i.d. for 15 days
Number of subjects: 155
Study 8112200 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP plasters
Number of subjects: 155
Study 8112200 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (PBO)
Number of subjects: 155
Study 3524418 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (250 mg amoxicillin and 125 mg clavulanic acid) administered every 8 h for 10 days
Number of subjects: 107
Study 3524418 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (250 mg) administered every 8 h for 10 days
Number of subjects: 107
Study 3524418 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 107
Study 3524418 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 107
Study 29607528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 50
Study 29607528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28841828 — intervention group
Group type: EXPERIMENTAL
Intervention: Blink rate assessment during conversation, average blink rate for patients with DIP was 14 (SD 11), and for patients without DIP was 19 (SD 14).
Number of subjects: 204
Study 28841828 — intervention group
Group type: EXPERIMENTAL
Intervention: Blink rate cut-off of 20 blinks per minute.
Number of subjects: 204
Study 28841828 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% percentile cut-off model for blink rate.
Number of subjects: 204
Study 28841828 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic prediction model between dichotomous DIP and continuous blink rate per minute.
Number of subjects: 204
Study 26552835 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxipoint therapy (NT)
Number of subjects: 97
Study 26552835 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy including transcutaneous electrical nerve stimulation (PT‐TENS)
Number of subjects: 97
Study 26552835 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-like treatments
Number of subjects: 97
Study 23668887 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP booster vaccine
Number of subjects: 9
Study 20583934 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose methotrexate
Number of subjects: 120
Study 20583934 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose methotrexate
Number of subjects: 120
Study 18218147 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium treatment (500 mg divided into two tablets for 8 weeks)
Number of subjects: 118
Study 18218147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 16247548 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic education plus conventional pharmacological treatment
Number of subjects: 43
Study 16247548 — intervention group
Group type: COMPARATOR
Intervention: Conventional pharmacological treatment only
Number of subjects: 43
Study 14615149 — intervention group
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN "new" vaccine 0.6 microg
Number of subjects: 405
Study 14615149 — intervention group
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN "new" vaccine 1.2 microg
Number of subjects: 405
Study 14615149 — intervention group
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN "new" vaccine 2.4 microg
Number of subjects: 405
Study 14615149 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 405
Study 10768308 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 97
Study 8706313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment (before treatment with methimazole)
Number of subjects: 12
Study 8706313 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated (after 11.2 ± 1.0 weeks treatment with methimazole)
Number of subjects: 12
Study 8706313 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 8706313 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg thrice daily for 2 days)
Number of subjects: 12
Study 7800160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (60-80 mg)
Number of subjects: 7
Study 7800160 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 7
Study 3050587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (n = 31)
Number of subjects: 74
Study 3050587 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (n = 43)
Number of subjects: 74
Study 3050587 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Cyclosporin A and Azathioprine)
Number of subjects: 74
Study 3050587 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Cyclosporin A and Azathioprine
Number of subjects: 74
Study 31615291 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban plus aspirin
Number of subjects: 27117
Study 31615291 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 27117
Study 31356105 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal lung recruitment
Number of subjects: 115
Study 31356105 — intervention group
Group type: COMPARATOR
Intervention: Control 'protective' ventilation
Number of subjects: 115
Study 29145345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex + Lokomat Training
Number of subjects: 40
Study 29145345 — intervention group
Group type: COMPARATOR
Intervention: Other antispastic drug + Lokomat Training
Number of subjects: 40
Study 25617992 — intervention group
Group type: EXPERIMENTAL
Intervention: FREE group (eye movements allowed)
Number of subjects: 0
Study 25617992 — intervention group
Group type: COMPARATOR
Intervention: FIX group (eye movements restricted)
Number of subjects: 0
Study 23434272 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-elastic basketweave taping
Number of subjects: 12
Study 23434272 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic adhesive bandage wrap
Number of subjects: 12
Study 23434272 — intervention group
Group type: COMPARATOR
Intervention: Non-taped control
Number of subjects: 12
Study 21159143 — intervention group
Group type: EXPERIMENTAL
Intervention: Three courses of platinum-based chemotherapy
Number of subjects: 0
Study 21159143 — intervention group
Group type: COMPARATOR
Intervention: Six courses of platinum-based chemotherapy
Number of subjects: 0
Study 21159143 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic process changes at the outpatient clinic
Number of subjects: 0
Study 21159143 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy use in a national population
Number of subjects: 0
Study 21159143 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy
Number of subjects: 0
Study 18337042 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted dose of 1.75 ml/kg
Number of subjects: 151
Study 18337042 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of 120 ml of non-ionic contrast material (320 mg/ml)
Number of subjects: 151
Study 17584356 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes outpatient intensive management programme (DOIMP)
Number of subjects: 49
Study 15332395 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 and 30 mg of doxorubicin
Number of subjects: 20
Study 15332395 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 and doxorubicin
Number of subjects: 20
Study 11293552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg HS
Number of subjects: 1674
Study 11293552 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin IR 40 mg HS
Number of subjects: 1674